• 치과방사선
• /
• 제23권2호
• /
• pp.379-384
• /
• 1993

The ameloblastic fibrosarcoma is the malignant counterpart of the ameloblastic fibrosarcoma in which the mesenchymal element has become malignant. Clinically it frequently occurs in the 3rd and 4th decades, and more frequent in the mandible than in the maxilla. Radiographic features are apparent multilocular radiolucency with ill-defined border. The authors experienced two cases of ameloblastic fibrosarcoma of the mandible in a 26-year-old male and a 48-year-old female patients who suffered from pain and swelling on the affected area. And we discussed the clinical, radiological and histopathological features of this disease with a brief review of the literatures.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제29권5호
• /
• pp.439-443
• /
• 2007

Ameloblastic fibrosarcoma(AFS) is a rare malignant odontogenic tumor presented as painful swelling and intraosseous mass with occasional ulceration. The most frequent site is the mandible body. AFS of the jaw generally occurs in all ages($3{\sim}83$ years old), with the average age of 27.3. AFS was associated with high local recurrence rate of 37% in the areas of gingiva, floor of mouth and neck. Although metastasis is not a special feature of this lesion, 20% have died within 3 months to 19 years, due to locally aggressive tumor growth. This report describes an ameloblastic fibrosarcoma occurring in the mandible of a twenty-five year old male. The tumor was treated by partial mandibulectomy and reconstructed with a fibular flap. The patient has shown no signs of recurrence or complications during 18 months postoperatively. In this study, we report our case with a review of literatures.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제41권3호
• /
• pp.139-144
• /
• 2015

Odontogenic carcinosarcoma is an extremely rare malignant odontogenic tumor with only a few reported cases. It is characterized by a true mixed tumor showing malignant cytology of both epithelial and mesenchymal components. It has been assumed to arise from pre-existing lesions such as ameloblastoma, ameloblastic fibroma, and ameloblastic fibrosarcoma. To date, the reported cases have exhibited considerably aggressive clinical behavior. The case of an odontogenic carcinosarcoma in the mandible of a 61-year-old male is described herein. The tumor destroyed the cortex of the mandible and invaded the adjacent tissues. Treatment was performed by surgical resection and reconstruction. The purposes of this article are to introduce odontogenic carcinosarcoma through this case study, to distinguish it from related diseases and to discuss features of the tumor in the existing literature.

• 한국임상수의학회지
• /
• 제28권6호
• /
• pp.603-606
• /
• 2011

11년 령의 중성화된 수컷 코커 스파니엘견이 구취, 식욕부진과 좌측 안면부의 부종 증상을 보여 내원하였다. 신체 검사 상에서 좌측 구강점막의 단단한 종괴가 확인되었다. 가는 침 흡인 세포검사 결과 악성의 중간엽 유래 종양이 가장 의심되어 생검을 실시하였고 조직검사 결과 섬유육종으로 진단되었다. 보호자의 거부로 수술적인 치료가 아닌 카보플라틴 (carboplatin, 300 $mg/m^2$, IV, q 21 days)을 이용한 항암치료를 실시하였다. 항암치료 시작 후 육안적으로 종양의 크기가 현저히 줄어들어 약 89일 후에는 육안적으로 완전 경감되었다. 총 4회의 항암치료 이후 항암치료를 중단하였고 종양의 재발은 일어나지 않았다. 본 증례보고는 개의 구강 섬유육종에서 carboplatin을 이용한 항암 치료가 육안적인 종양의 완전 경감을 유도할 수 있음을 보여준다.

• Imaging Science in Dentistry
• /
• 제41권2호
• /
• pp.85-88
• /
• 2011

Central odontogenic fibroma is a rare odontogenic neoplasm that originates from odontogenic ectomesenchyme. Here, a case of central odontogenic fibroma in a 17-year-old male is reported. Since the present case showed a multilocular radiolucency with partially ill-defined border between the right mandibular condyle and the distal root of the right mandibular third molar, differential diagnosis involved a wide range of pathosis from benign lesions like ameoloblastic fibroma and odontogenic myxoma to more aggressive lesions such as desmoplastic fibroma, juvenile aggressive fibromatosis, or fibrosarcoma.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제33권1호
• /
• pp.55-58
• /
• 2007

The fibromatoses are a broad group of fibrous proliferations. They have a biologic behavior and histopathologic pattern that is intermediate between those of benign fibrous lesions and fibrosarcoma. Because they are not common diseases, it is important to differentiate the fibromatoses from other similar diseases. In this report, we present a case of fibromatosis, and possible other diseases to be differentiated, with a review of literatures.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제16권2호
• /
• pp.186-195
• /
• 1994

Fibromatosis is benign fibroblastic proliferative lesion with abundant collagenous neo-formation located principally in the abdominal wall and in the upper and lower extremities (Masson & Soule, 1966). Wilkins and Waldron, in 1975, suggested that the title aggressive fibromatosis was a more appropriate term, reflecting the invasive characteristics of the disease. Synonyms listed were extra-abdominal desmoid, juvenile fibromatosis, aggressive infantile fibromatosis and congenital fibrosarcoma. A total of 12% of all fibromatosis arise in head and neck. Fibromatosis of the oral cavity is uncommon and is even more rare when in involve the mandibule. It is a locally aggressive fibrous tissue tumor, generally does not metastasize, but may cause considerable morbility and even death due to local infiltration. The degree of microscopic cellularity is variable, not only from tumor to tumor but also from area to area in the same tumor. Some tumors present with proliferation of mature fibroblasts and a dominating collagenous component : others may show a lack of the tumor in both types. The common histologic denominator appears to be cellular interlacing bundles of elongated fibroblasts, showing little or no mitotic activity and no pleomorphism. Mitosis are not a consistent index of malignancy when found in younger age groups. Fibromatosis still posses difficult problems of diagnosis and treatment. It is frequently recurrent and infliltrates neighbouring tissues. These lesion infliltrate widely and replace muscle, fat, and even bone with fibrous tissue of varying cellularity. Lesion representing fibromatosis in the oral cavity must be carefully evaulated by both surgeon and pathologists to ensure proper diagnosis and treatment planning. When these lesions involve bone, surgeon must be aware of the lesion's potential to perforate the cortex and expand while remaining hidden from the surgeon's view. Careful and precise clinical correlation with histologic appearance is essential to preclude misdiagnosis of fibrosarcoma yet provide surgical treatment plan that provides adequate local excision and long-term follow up. As regards cause, little is known. It is attributed to trauma or alteration in the sex hormone(Carlos, et al, 1986). Clinially, the lesion is reported to be not painful in most cases, but capable of rapid growth. The treatment is essentially surgical excision with wide margin of adjacent uninvolved tissue. Radiotherapy, hormone treatment or chemotherapy are of no use (WIkins et al, 1975 ; Majumudar and Winiarkl, 1978). We report a case of aggressive fibromatosis of 15-year-old with a lesion in the soft tissue of the parotid area that invaded the underlying bone of the mandibular body.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제35권5호
• /
• pp.277-283
• /
• 2013

Purpose: Well vascularized pectoralis major myocutaneous flap (PMMF) had been a commonly used versatile flap in reconstructive oromaxillofacial surgery since the 1970s. However, after the advent of microvascular surgery in the 1980s, the PMMF was used less frequently. But, to date, PMMF has been useful and has some advantages such as covering wide defects, covering vital structures, back-up procedure in cases of free flap failure, and reconstruction for radiotherapy patients. The purpose of this study is to evaluate the role, indication, complications, functional, and aesthetic results of this flap in the era of free flap with a literature and chart review. Methods: A retrospective study was conducted of 16 oral cancer patients undergoing reconstructive surgery with PMMF for reconstruction of defects from 2001 to 2012 at Kyungpook National University Hospital. The male to female ratio was 10:6, with a mean age of 63 years (16~79 years). Basic demographic data, previous treatment history, indications, dimension of the flap, site of reconstruction, postoperative complications, and patients' final status were systemically analyzed from chart review. Results: The pathology of the disease included squamous cell carcinoma in the majority of cases (n=14). The remaining cases were fibrosarcoma and mucoepidermoid carcinoma. Of the 16 PMMF reconstructions, 13 flaps were applied as primary reconstructive procedures, whereas three flaps were; salvage; procedures (vascularized free flap failure). Twelve patients had complications such as wound dehiscence, infection, hematoma, fistula, flap bulkiness, and partial flap necrosis. The higher complication rates showed an association with utilization of the flap in preoperative radiotherapy cases. However, all patients were discharged without failure. Conclusion: In reconstructive oromaxillofacial surgery, the PMMF is still a useful flap for huge defects. In addition, the PMMF can be used as a salvage procedure after vascularized free flap failure and reconstruction for patients with a history of preoperative radiotherapy.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제27권4호
• /
• pp.314-320
• /
• 2001

Matrix metalloproteinases have long been viewed as ideal candidates for proteinases that enables tumor cells to permeated basement membrane defenses and invade surrounding tissue. There is growing evidence that the MMPs have an expanded role, as they are important for the creation and maintenance of a microenvironment that facilitates growth and angiogenesis of tumors at primary and metastatic sites. MT-MMPs are not secreted but instead remaining attached to cell surfaces. Although not all of the MT-MMPs are fully characterized, MT-MMPs have important role in localizing and activating secreted MMPs. The MMP genes are transcriptionally responsive to a wide variety of oncogene, growth factors, cytokine, and hormones. Currently, a number of MMP inhibitors are being developed and some have reached clinical trials as anti-metastatic or anti-cancer therapies. MT1-MMP is involved in the activation of proMMP-2. MT1-MMP is significant not only as a tumor marker but as a new target for chemotherapy against cancer. The purpose of this study was to evaluate the effects of protein kinase C inhibitor(genistein) on the proliferation of HT1080 and expression of MT1-MMP mRNA. Human fibrosarcoma cell line HT1080 was cultured and divided 2 groups. The experimental group was treated with $100{\mu}M$ genistein and incubated 12h, 24h for $[3^H]-thymidine$ uptake assay and northern hybridization individually. And the control group was treated with same amount of PBS for the above procedures. $[3^H]-thymidine$ incorporation was measured with ${\beta}$ ray detector. And RT-PCR and northern blotting for MT1-MMP mRNA was performed. The results were as follows 1. $[3^H]-thymidine$ uptake was reduced in experimental group with statistical significance. 2. MT1-MMP mRNA expression was significantly reduced in experimental group. These results showed that protein kinase C inhibitor (genistein) inhibited proliferation of HT1080 and almost completely blocked transcription of MT1-MMP mRNA. So, it is possible to use the protein kinase inhibitor (genistein) as anti-metastatic and anti-proliferative agent.

• 한국임상수의학회:학술대회논문집
• /
• 한국임상수의학회 2006년도 춘계학술대회
• /
• pp.152-152
• /
• 2006